Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADR010
MIFTS: 40

Adrenal Cortical Hypofunction

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Adrenal Cortical Hypofunction

About this section

MalaCards integrated aliases for Adrenal Cortical Hypofunction:

Name: Adrenal Cortical Hypofunction 12 15 73
Adrenal Cortical Insufficiency 12
Corticoadrenal Insufficiency 12

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:10493
ICD9CM 35 255.4
NCIt 50 C26691
UMLS 73 C0405580
Sources

Summaries for Adrenal Cortical Hypofunction

About this section
MalaCards based summary : Adrenal Cortical Hypofunction, also known as adrenal cortical insufficiency, is related to adrenal hypoplasia, congenital and hypoadrenocorticism, familial. An important gene associated with Adrenal Cortical Hypofunction is NR0B1 (Nuclear Receptor Subfamily 0 Group B Member 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Metabolism of steroid hormones. The drugs Epinephrine and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and pituitary, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Adrenal Cortical Hypofunction

About this section

Diseases related to Adrenal Cortical Hypofunction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Related Disease Score Top Affiliating Genes
1 adrenal hypoplasia, congenital 31.3 GK IL1RAPL1 NR0B1 NR5A1
2 hypoadrenocorticism, familial 29.7 AIRE CRH CYP11A1 CYP21A2 NR0B1 POMC
3 premature ovarian failure 7 11.6
4 achalasia-addisonianism-alacrima syndrome 11.2
5 hypothalamic disease 10.7 CRH POMC
6 pituitary carcinoma 10.7 CRH POMC
7 46,xy partial gonadal dysgenesis 10.7 NR0B1 NR5A1
8 type 1 diabetes mellitus 17 10.7 AIRE TNFRSF25
9 acth deficiency, isolated 10.7 CRH POMC
10 nelson syndrome 10.6 CRH POMC
11 sheehan syndrome 10.6 CRH POMC
12 46,xx sex reversal 1 10.6 NR0B1 NR5A1
13 hypoadrenalism 10.6 CRH POMC
14 acth-secreting pituitary adenoma 10.6 CRH POMC
15 fasting hypoglycemia 10.6 CRH POMC
16 intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 10.6 GK NR0B1
17 pyle disease 10.6 AIRE NR0B1
18 withdrawal disorder 10.5 CRH POMC
19 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 10.5 CYP21A2 POMC
20 cytochrome p450 oxidoreductase deficiency 10.5 CYP21A2 POMC
21 ectopic cushing syndrome 10.4 CRH POMC
22 persistent fetal circulation syndrome 10.3 CRH POMC
23 hypoaldosteronism 10.3 POMC REN
24 amenorrhea 10.3 CRH NR5A1 POMC
25 inappropriate adh syndrome 10.3 POMC REN
26 autoimmune polyendocrine syndrome type 1 10.3 AIRE CYP21A2
27 46 xy gonadal dysgenesis 10.3 CYP11A1 NR0B1 NR5A1
28 alternating hemiplegia of childhood 10.2 GK NR0B1 NR5A1
29 vitiligo-associated multiple autoimmune disease susceptibility 1 10.2 AIRE POMC PTPN22
30 type 1 diabetes mellitus 5 10.2 AIRE TNFRSF25
31 sex differentiation disease 10.2 CYP21A2 POMC
32 autoimmune disease of endocrine system 10.2 AIRE PTPN22 TNFRSF25
33 hyperaldosteronism, familial, type i 10.2 POMC REN
34 pituitary-dependent cushing's disease 10.2 CRH CYP21A2 POMC
35 adrenal gland hyperfunction 10.1 CRH CYP21A2 POMC
36 malignant essential hypertension 10.1 REN TNFRSF25
37 adrenal rest tumor 10.1 CYP21A2 NR5A1 POMC
38 familial glucocorticoid deficiency 10.1 NR0B1 POMC REN
39 gonadal disease 10.1 CRH NR0B1 NR5A1 POMC
40 testicular leydig cell tumor 10.1 CYP11A1 CYP21A2 POMC
41 steroid inherited metabolic disorder 10.1 CYP11A1 CYP21A2 POMC
42 chromosome xp21 deletion syndrome 10.1 GK IL1RAPL1 NR0B1
43 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 10.1 AIRE CYP11A1 CYP21A2
44 adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete 10.1 CYP11A1 CYP21A2 POMC
45 apparent mineralocorticoid excess 10.1 POMC REN
46 glycerol kinase deficiency 10.1 GK IL1RAPL1 NR0B1
47 premenstrual tension 10.1 CRH POMC REN
48 aldosterone-producing adenoma 10.0 CYP21A2 REN
49 endocrine organ benign neoplasm 10.0 CRH POMC REN
50 diabetes insipidus 10.0 CRH POMC REN

Graphical network of the top 20 diseases related to Adrenal Cortical Hypofunction:



Diseases related to Adrenal Cortical Hypofunction
Sources

Symptoms & Phenotypes for Adrenal Cortical Hypofunction

About this section

GenomeRNAi Phenotypes related to Adrenal Cortical Hypofunction according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.6 POMC
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.6 GK NR5A1 POMC
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.6 GK
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.6 GK
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.6 POMC
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.6 NR5A1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.6 GK
8 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.6 NR5A1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.6 POMC
10 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.6 GK
11 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.6 POMC
12 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.6 NR5A1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.6 GK NR5A1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.6 GK
15 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.6 POMC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.6 POMC

MGI Mouse Phenotypes related to Adrenal Cortical Hypofunction:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.23 AIRE CRH CYP11A1 NR0B1 NR5A1 POMC
Sources

Drugs & Therapeutics for Adrenal Cortical Hypofunction

About this section

Drugs for Adrenal Cortical Hypofunction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-43-4 5816
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-23-7 5754
3
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 329-65-7 838
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 50-02-2 5743
5
Fludrocortisone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 127-31-1 31378
6
Cosyntropin Approved Phase 4,Phase 3,Not Applicable 16960-16-0 16129617
7
Menthol Approved Phase 4 2216-51-5 16666
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
9
Cortisone acetate Approved, Investigational Phase 4,Not Applicable 1950-04-4, 50-04-4 5745
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
12
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
13
Etomidate Approved Phase 4,Phase 2,Phase 3,Not Applicable 33125-97-2 36339 667484
14
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 2078-54-8 4943
15
Celecoxib Approved, Investigational Phase 4,Phase 2 169590-42-5 2662
16
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
17
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
18
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3 6740-88-1 3821
19
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
20 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
21
Butyric Acid Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 107-92-6 264
22 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Cortisol succinate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Epinephryl borate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Hydrocortisone acetate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Hydrocortisone-17-butyrate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Liver Extracts Phase 4,Phase 3,Phase 2
33 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Adrenergic beta-Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 BB 1101 Phase 4,Phase 1,Not Applicable
40 Bronchodilator Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Dexamethasone acetate Phase 4,Phase 1,Not Applicable 1177-87-3
42 Mydriatics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Vasoconstrictor Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Adrenocorticotropic Hormone Phase 4,Phase 1,Not Applicable
49 Antiemetics Phase 4,Phase 3,Phase 1,Not Applicable
50 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 184)
# Name Status NCT ID Phase Drugs
1 Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT00773058 Phase 4 hydrocortisone;placebo
2 Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function Unknown status NCT02206256 Phase 4 Omega-3 fatty acid capsules
3 Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment Completed NCT00975078 Phase 4 prednisone
4 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
5 Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT) Completed NCT01546922 Phase 4 Hydrocortisone
6 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Completed NCT00851942 Phase 4 Synacthen (Tetracosactrin)
7 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
8 Post Operative Hemodynamic Function After Anesthetic Induction With Etomidate for Cardiac Surgery With ECC Completed NCT00451776 Phase 4 etomidate;propofol
9 The Effect of Moderate-Dose Steroid Therapy in Sepsis Completed NCT01275638 Phase 4 Prednisolone
10 Low-dose Hydrocortisone in Acutely Burned Patients Completed NCT00149123 Phase 4 hydrocortisone 200 mg/day
11 Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery Completed NCT00415701 Phase 4 Etomidate;Propofol;Hydrocortisone;NaCl 0.9%
12 Short-term Prednisone to Treat STA Study(SPTSS) Completed NCT01837433 Phase 4 Prednisone 1 week;Prednisone 6 weeks
13 Steroid Use in Pediatric Fluid and Vasoactive Infusion Dependent Shock - Pilot Study Completed NCT02044159 Phase 4 Hydrocortisone
14 Revival of Stem Cells in Addison's Study Completed NCT01371526 Phase 4 depot tetracosactide
15 Taper Or Abrupt Steroid Stop: TOASSTtrial Recruiting NCT03153527 Phase 4 Prednisone
16 Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients Recruiting NCT02997605 Phase 4 GlucoCorticoid
17 Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial Recruiting NCT02643381 Phase 4 Etomidate;Ketamine
18 Corticosteroid Reduction in COPD Recruiting NCT02857842 Phase 4 Prednisolone
19 Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis Recruiting NCT03265405 Phase 4 Low dose prednisolone;Medium dose prednisolone
20 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites Recruiting NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
21 Optimising Steroid Replacement in Patients With Adrenal Insufficiency Enrolling by invitation NCT03282487 Phase 4 Modified release hydrocortisone
22 Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism Enrolling by invitation NCT02282150 Phase 4 Hydrocortisone;Plenadren
23 A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT) Not yet recruiting NCT03210545 Phase 4 Dexamethasone
24 Adrenal Insufficiency in Septic Shock Terminated NCT00842933 Phase 4 Corticosteroid;Corticosteroid
25 Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency Terminated NCT01089075 Phase 4 Hydrocortisone;Placebo
26 Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock Terminated NCT01150409 Phase 4 hydrocortisone;Normal Saline
27 Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis Withdrawn NCT00368381 Phase 4 Hydrocortisone
28 The Effect of Dexamethasone on Cortisol Levels in Patients Undergoing Thyroid Surgery Withdrawn NCT01045876 Phase 4 Dexamethasone
29 Septic Shock em Steroids Unknown status NCT01047670 Phase 2, Phase 3 Hydrocortisone
30 Treatment of Adrenal Insufficiency in Children Completed NCT02720952 Phase 3 Infacort®
31 Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency Completed NCT00915343 Phase 2, Phase 3 hydrocortisone (modified release), oral tablet 20 and 5 mg;Hydrocortisone, oral tablet, 10 mg
32 Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency Completed NCT00575341 Phase 3 Dehydroepiandrosterone;placebo
33 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency Completed NCT00004313 Phase 3 dehydroepiandrosterone
34 Treatment of Polytraumatisms With Corticoids Completed NCT00563303 Phase 2, Phase 3 hydrocortisone;NaCl
35 Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury Completed NCT01093261 Phase 3 Placebo;Hydrocortisone Fludrocortisone
36 PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates Completed NCT00623740 Phase 3 hydrocortisone;placebo
37 Early Use of Hydrocortisone in Hypotensive Very Low Birth Weight Infants Completed NCT00358748 Phase 3 Hydrocortisone
38 Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma Completed NCT01691508 Phase 3 Mepolizumab;Placebo;OCS (prednisone/prednisolone)
39 Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock Completed NCT00320099 Phase 3 recombinant human insulin;hydrocortisone;fludrocortisone;Hydrocortisone
40 Corticosteroid Therapy of Septic Shock - Corticus Completed NCT00147004 Phase 3 hydrocortisone sodium succinate;Placebo
41 Glucocorticoid Treatment in Addison's Disease Completed NCT01063569 Phase 2, Phase 3 Solu-Cortef (hydrocortisone);Cortef (hydrocortisone)
42 MD1003-AMN MD1003 in Adrenomyeloneuropathy Completed NCT02961803 Phase 2, Phase 3 MD1003 100 mg capsule;Placebo
43 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
44 Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Completed NCT00007020 Phase 3 Cholic Acids
45 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients? Recruiting NCT03368066 Phase 3 Cosyntropin
46 A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Recruiting NCT03231878 Phase 2, Phase 3 MIN-102;Placebos
47 Extension Study for Patients Entered Into Study Infacort 003 Active, not recruiting NCT02733367 Phase 3 Infacort®
48 Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns Active, not recruiting NCT02700828 Phase 2, Phase 3 Hydrocortisone;Placebo
49 Ketamine / Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial Active, not recruiting NCT02105415 Phase 2, Phase 3 Ketamine / Propofol Admixture;Etomidate
50 A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD) Active, not recruiting NCT01896102 Phase 2, Phase 3

Search NIH Clinical Center for Adrenal Cortical Hypofunction

Sources

Genetic Tests for Adrenal Cortical Hypofunction

About this section
Sources

Anatomical Context for Adrenal Cortical Hypofunction

About this section

MalaCards organs/tissues related to Adrenal Cortical Hypofunction:

41
Testes, Brain, Pituitary, Thyroid, Lung, Kidney, Bone
Sources

Publications for Adrenal Cortical Hypofunction

About this section

Articles related to Adrenal Cortical Hypofunction:

# Title Authors Year
1
Occurrence of allergic disease in patients with adrenal cortical hypofunction. ( 13807987 )
1960
2
Adrenal cortical hypofunction in some cases of chronic amoebiasis. ( 13620929 )
1958
3
Eight patients with adrenal cortical hypofunction surviving more than fifteen years. ( 13271108 )
1955
4
Adrenogenital virilism with adrenal cortical hypofunction; a clinical entity. ( 14361534 )
1955
5
Oral therapy of adrenal cortical hypofunction; use of combined fluorocortisone acetate and hydrocortisone. ( 13271094 )
1955
6
Arthritis following use of desoxycorticosterone acetate and cortisone; occurrence in patient with adrenal cortical hypofunction. ( 14353638 )
1955
7
Temporary adrenal cortical hypofunction in newborns. ( 12984012 )
1952
Sources

Variations for Adrenal Cortical Hypofunction

About this section
Sources

Expression for Adrenal Cortical Hypofunction

About this section
Search GEO for disease gene expression data for Adrenal Cortical Hypofunction.
Sources

Pathways for Adrenal Cortical Hypofunction

About this section

Pathways related to Adrenal Cortical Hypofunction according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Aldosterone synthesis and secretion 37
Show member pathways
 12.52 CRH CYP11A1 CYP21A2 NR5A1 POMC
2
Metabolism of steroid hormones 66
Show member pathways
 11.28 CYP11A1 CYP21A2 POMC
3
Corticotropin-releasing hormone signaling pathway 1
10.89 CRH CYP11A1 CYP21A2 POMC
4
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 61
9.8 CRH POMC
Sources

GO Terms for Adrenal Cortical Hypofunction

About this section

Biological processes related to Adrenal Cortical Hypofunction according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.65 PTPN22 REN TNFRSF25
2 steroid metabolic process GO:0008202 9.61 CRH CYP11A1 CYP21A2
3 male gonad development GO:0008584 9.54 NR0B1 NR5A1 REN
4 negative regulation of tumor necrosis factor production GO:0032720 9.49 POMC PTPN22
5 sterol metabolic process GO:0016125 9.46 CYP11A1 CYP21A2
6 steroid biosynthetic process GO:0006694 9.43 CYP11A1 CYP21A2 NR0B1
7 hypothalamus development GO:0021854 9.4 CRH NR0B1
8 response to immobilization stress GO:0035902 9.33 CRH NR0B1 REN
9 sex determination GO:0007530 9.32 NR0B1 NR5A1
10 adrenal gland development GO:0030325 9.13 CRH NR0B1 NR5A1
11 glucocorticoid biosynthetic process GO:0006704 8.8 CRH CYP11A1 CYP21A2

Molecular functions related to Adrenal Cortical Hypofunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 CRH POMC
2 signaling receptor binding GO:0005102 8.92 CRH IL1RAPL1 POMC REN
Sources

Sources for Adrenal Cortical Hypofunction

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....